Fig. 4From: Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)Proportions of patients reporting minimal clinically important improvement in Health Assessment Questionnaire-Disability Index (HAQ-DI decrease from baseline of ≥ 0.22) over 84 weeks (full analysis set; NRI). NRI, nonresponder imputation; QD, once dailyBack to article page